Skip to main content
Premium Trial:

Request an Annual Quote

To the Hotspots

Pharmaceutical companies are investing in shifting their operations to a few bioscience hotspots, even at a time of cutbacks, says this Wall Street Journal article. While cities like Boston and San Francisco are being helped by companies' relocations and the construction it entails, the suburban areas being left like New Jersey and Connecticut are not doing as well. "Companies are able to offset the high costs of operating in established clusters with the increased odds of innovation due to deep, rich talent pools and infrastructure," says a report from real-estate advisory firm Jones Lang LaSalle.

"The micro environment really matters," adds Pfizer's Rod MacKenzie. "It really is helpful if you are right next door to scientists and other institutions."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.